24 Investor presentation First three months of 2021 Continued single digit volume gr segments globally Long-acting insulin tMU Premix i tMU 250 CAGR volume 1 : 4.9% 100% 160 CAGR volum MI penetration 2 : 77.5% MI penetrati 200 80% 120 150 60% 80 100 40% 40 50 20% 0 Feb 2016 Segment volume Tresiba ® Feb 0% 2021 Levemir ® Combined 0 Feb 2016 Segment volume Ryzodeg ® 1 CAGR for 5-year period 2 Includes new-generation insulin. tMU: Thousand mega units; NN: Novo Nordisk Note : Modern insulin (MI) penetration is of total segment, i.e. including animal and human insulin; Data is sensitive to changes in I Source: IQVIA MAT, Feb 2021 volume figures
Download PDF file